-
Jefferies Raises Its PT on Hologic to $24 (HOLX)
Tuesday, February 1, 2011 - 11:45am | 121Jefferies is out with its report today on Hologic (NASDAQ: HOLX), raising its PT from $21 to $24. In a note to clients, Jefferies writes, "We are raising our PT to $24 from $21 to reflect expanded forward med-tech multiples (currently trading 18.0x on a forward P/E basis) coupled with greater...
-
C.R. Bard's Mixed 4Q, Profit Zooms - Analyst Blog
Tuesday, February 1, 2011 - 11:45am | 988Leading medical devices maker C. R. Bard (BCR) reported fourth-quarter fiscal 2010 results after the closing bell on January 31, with an adjusted earnings per share of $1.54 topping the Zacks Consensus Estimate of $1.48 while surpassing the year-ago earnings of $1.39. For fiscal 2010, adjusted...
-
Earnings Scorecard: Intuitive - Analyst Blog
Tuesday, February 1, 2011 - 10:31am | 1043Intuitive Surgical (ISRG) reported favorable fourth-quarter 2010 results on January 20. Earnings per share came in at $3.02, beating the Zacks Consensus Estimate of $2.26. Fourth Quarter Review Revenues increased 21% year over year to $389 million, beating the Zacks Consensus Estimate by $17...
-
Earnings Scorecard: Intuitive - Analyst Blog
Tuesday, February 1, 2011 - 10:15am | 1043Intuitive Surgical (ISRG) reported favorable fourth-quarter 2010 results on January 20. Earnings per share came in at $3.02, beating the Zacks Consensus Estimate of $2.26. Fourth Quarter Review Revenues increased 21% year over year to $389 million, beating the Zacks Consensus Estimate by $17...
-
Piper Jaffray Raises PT On C.R. Bard To $93
Tuesday, February 1, 2011 - 9:42am | 28Piper Jaffray has raised the price target on C.R. Bard (NYSE: BCR) from $89 to $93 and maintains its Neutral rating.
-
ResMed Inc. Announces CEO Resignation
Tuesday, February 1, 2011 - 9:40am | 95ResMed Inc. (NYSE: RMD) today announced changes to its management team. Kieran T. Gallahue has resigned his position as Chief Executive Officer and President, and as a director, effective January 28, 2011. The board has appointed Dr. Peter C. Farrell, ResMed's founder and executive chairman, to...
-
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Tuesday, February 1, 2011 - 9:24am | 297Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Accuray Inc (ARAY) Apple Inc (AAPL) ATMI Inc (ATMI) BASF ADR (BASFY) Centrica PLC (CPYYY) View the entire Zacks #1 Rank List. APPLE INC (AAPL): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report ATMI...
-
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Tuesday, February 1, 2011 - 9:14am | 297Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Accuray Inc (ARAY) Apple Inc (AAPL) ATMI Inc (ATMI) BASF ADR (BASFY) Centrica PLC (CPYYY) View the entire Zacks #1 Rank List. APPLE INC (AAPL): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report ATMI...
-
Morgan Keegan Provides Color On BCR 4Q
Tuesday, February 1, 2011 - 9:12am | 163C.R. Bard, Inc. (NYSE: BCR) reported 4Q results with in-line sales and EPS of $1.54 “versus our $1.50 estimate and Street consensus of $1.48,” Morgan Keegan reports. “Although the company picked up its SG&A investment in the quarter, it achieved EPS outperformance by the reinstatement of the R...
-
Piper Jaffray Previews Boston Scientific's Q4 10 Earnings (BSX)
Tuesday, February 1, 2011 - 9:05am | 105Piper Jaffray is out with its report on Boston Scientific (NYSE: BSX), previewing Q4 10 earnings before they are announced this evening. In a note to clients, Piper Jaffray writes, "Barring a major miss relative to expectations, we think Q4 results are largely academic with the focus largely on the...
-
Jefferies Raises PT on Hologic To $24
Tuesday, February 1, 2011 - 8:54am | 26Jefferies & Company has raised the price target on Hologic (NASDAQ: HOLX) from $21 to $24 and maintains its Buy rating.
-
Kensey Nash Reports Q3 EPS of $.38 vs. $.39
Tuesday, February 1, 2011 - 8:39am | 87Kensey Nash Corporation (Nasdaq: KNSY) today reported the results for its second quarter ended December 31, 2010. Diluted EPS of $0.38, in line with the Company's previous guidance of $0.37-$0.40, and representing an increase from the prior year comparable quarter's diluted EPS of $0.32 and a...
-
JP Morgan Raises PT On C.R. Bard To $97
Tuesday, February 1, 2011 - 8:26am | 28JP Morgan has raised the price target on C.R. Bard (NYSE: BCR) from $95 to $97 and maintains its Neutral rating.
-
JP Morgan Raises PT On Hologic To $21
Tuesday, February 1, 2011 - 8:20am | 26JP Morgan has raised the price target on Hologic (NASDAQ: HOLX) from $20 to $21 and maintains its Overweight rating.
-
US Stock Futures Up As Investors Await Economic Data, Earnings Reports; Pfizer Results In Focus
Tuesday, February 1, 2011 - 7:46am | 386US stock futures are higher this morning, as investors are awaiting earnings from Pfizer Inc (NYSE: PFE) and other major companies. Futures on the Dow Jones Industrial Average advanced 43 points to 11,883.00 and S&P 500 futures gained 6.60 points to 1,289.00. Nasdaq 100 futures climbed 14.50...